Public Company News
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-10-20 09:00
2538
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041)...
2025-10-20 08:15
3047
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure...
2025-10-20 08:10
3135
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) ofsmall molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The ult...
2025-10-20 08:10
2460
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2025-10-20 07:00
1890
Webull Reduces Minimum ASX Trading Fee To $1
* Webull Australia now offers the lowest-cost CHESS-sponsored brokerage fee minimums for trading ASX shares * The new pricing structure is paired with Webull's industry-leading technology and free live pricing data * $1.00 minimum fees will be made available to Australian clients from 20 Oc...
2025-10-20 06:00
3076
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Ak...
2025-10-19 23:42
2225
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
* Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. * The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination th...
2025-10-19 23:37
2139
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically...
2025-10-19 14:00
2464
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cel...
2025-10-18 22:46
3013
Manulife Hong Kong and JUST FEEL Promote Emotional Well-Being with City's First "My Flag Day"
500 family volunteers distribute over 10,000 free flags to encourage the public to share their feelings HONG KONG, Oct. 18, 2025 /PRNewswire/ -- Manulife Hong Kong and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held the city's first-ever "My Flag Day" today. ...
2025-10-18 16:23
3882
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholl...
2025-10-18 14:59
2770
Yunji Technology Debuts on HKEX, Partners with Luxshare Precision to Accelerate Global Expansion
HONG KONG, Oct. 18, 2025 /PRNewswire/ -- Beijing Yunji Technology Co., Ltd.
(the "Company"; Stock code: 2670) today announced that shares of the Company
have started to be traded on the Main Board of The Stock Exchange of Hong Kong
Limited under the stock code "2670".
2025-10-18 10:12
4640
Agoda Joins as Main Sponsor of Singapore's Iconic #HuntTheMouse Cash Hunt
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- Digital travel platform Agoda has signed up as a main sponsor for the much-anticipated #HuntTheMouse cash hunt in Singapore. Running from 16 October to 14 December 2025, the event is organized by Singaporean company Sqkii and offers participants a chance to...
2025-10-18 09:19
2647
PINTEC's Subsidiary ZIITECH Makes Its Debut at Tech Week Singapore 2025
BEIJING, Oct. 17, 2025 /PRNewswire/ -- Pintec Technology Holdings Limited (Nasdaq: PT) ("PINTEC" or the "Company"), a leading technology platform committed to enabling innovative financial and digital solutions for businesses worldwide, today announced that its subsidiary ZIITECH PTY LTD ("ZIITEC...
2025-10-18 04:05
3985
CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2025
HONG KONG, Oct. 17, 2025 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced its financial results for the six months and full year of fiscal 2025 ended June 30, 2025. During this fiscal year, we faced a significant challenge when our long-standing and hi...
2025-10-17 21:23
5386
NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension
NEW YORK, Oct. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Automakers await 5-ye...
2025-10-17 20:55
2665
SparkRWA Expands AI Applications to Empower the Global Green Economy and Drive Sustainable Innovation
HONG KONG, Oct. 17, 2025 /PRNewswire/ -- GIBO Holdings Ltd. (NASDAQ: GIBO), Asia's leading innovation-driven creative ecosystem, today announced an extended application of its proprietary AI technologies under theSparkRWA Green Creator Framework, marking a major step toward integrating artificial...
2025-10-17 20:43
3046
Re-imagining Neo-Pragmatic Lifestyle: EPWK Launches Strategic Upgrade with "EPWK Curated Goods"
XIAMEN, China, Oct. 17, 2025 /PRNewswire/ -- "We grew weary of life's monotony, so we embarked on a journey to find 'EPWK Curated Goods.' Each selected item must pass our stringent 'Three Goods' standard: Good-looking, Good-to-use, and Good-surprise. We believe that truly excellent products can i...
2025-10-17 20:36
1961
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketi...
2025-10-17 20:22
2472
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 291 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 288 media titles]
2026-05-27 09:16
Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
7106
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
6149
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
6133
